Friday, September 04, 2009
Ranbaxy generic Rocaltrol
Reuters
Indian drugmaker Ranbaxy Laboratories Ltd said on Thursday it would launch in the United States a generic version of Rocaltrol used in the treatment of ailments arising from renal failure. Ranbaxy will market the drug, which has annual sales worth $70 million, in an agreement with Validus Pharmaceuticals, a U.S.-based company focused on acquiring and marketing prescription drugs.
Ranbaxy, in which Japan's Daiichi Sankyo bought about 64 percent last year, said in a statement it would launch the drug immediately and expected to be the only firm offering the generic version of Rocaltrol.
Indian drugmaker Ranbaxy Laboratories Ltd said on Thursday it would launch in the United States a generic version of Rocaltrol used in the treatment of ailments arising from renal failure. Ranbaxy will market the drug, which has annual sales worth $70 million, in an agreement with Validus Pharmaceuticals, a U.S.-based company focused on acquiring and marketing prescription drugs.
Ranbaxy, in which Japan's Daiichi Sankyo bought about 64 percent last year, said in a statement it would launch the drug immediately and expected to be the only firm offering the generic version of Rocaltrol.
